Edgewise Therapeutics, Inc. Lock-Up Agreement September 12, 2022Orbimed Advisors LLC • September 16th, 2022 • Pharmaceutical preparations • New York
The undersigned understands that J.P. Morgan Securities LLC and SVB Securities LLC, as representatives (the “Representatives”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the “Underwriters”), with Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), providing for a public offering (the “Public Offering”) of shares of the Common Stock of the Company (the “Shares”) pursuant to a shelf Registration Statement on Form S-3 that has been previously filed with the Securities and Exchange Commission (the “SEC”).
JOINT FILING AGREEMENTJoint Filing Agreement • September 16th, 2022 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on Schedule 13D, dated September 16, 2022, with respect to the common stock of Edgewise Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
